EVGN Nov 2024 2.500 call
| Previous Close | 0.0500 |
| Open | 0.0200 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 2.50 |
| Expire Date | 2024-11-15 |
| Day's Range | 0.0200 - 0.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 162 |
PR NewswireCasterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country
Casterra Ag Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), is a provider of an integrated solution for industrial-scale cultivation of castor plants based on its elite castor seed varieties, developed for bio-based industries including, biofuels & biopolymers. Casterra is pleased to announce the receipt of an additional purchase order valued at ~$440K from an existing customer. This order expands Casterra's operations into a new African country and solidifies Casterra's unique o
PR NewswireBiomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced encouraging initial findings from an ongoing Phase 1 clinical trial. In the study, Biomica is investigating the safety and tolerability of its microbiome-based immuno-oncology candidate, BMC128, in combination with nivolumab, an anti-PD1 immune checkpoint inhibitor, in patients with non-small cell lung cancer (N
PR NewswireEvogene Reports First Quarter 2024 Financial Results
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based products, today announced its financial results for the first quarter period ended March 31, 2024.
